Therapeutic Target Details
| Target ID: | T25 |
| Target Name: | C-C chemokine receptor type 5 |
| Synonyms: | C-C CKR-5; CHEMR13; CMKBR5; HIV-1 fusion coreceptor; CCR5 |
| GENE: | CCR5 |
| Action: | antagonist |
| Class: | GPCR |
| UniProtKB ID: | P51681 |
| Entry Name: | CCR5_HUMAN |
| Related Drugs: | Cenicriviroc |
| Mechanism: | CCR5 in the activation and proliferation of collagen-producing activated hepatic stellate cells/myofibroblasts. C motif chemokine receptor types 2 and 5 are both involved in the inflammatory and fibrogenic pathways. |
| Reference (PMIDs): | 32381514 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D067 | Celsentri | Chemical drug | DB04835 | -- | -- | Under clinical trials | Details |
| D216 | Maraviroc | Chemical drug | DB04835 | CCR5 antagonist; CCR5 binder | Anti-fibrosis | Under clinical trials | Details |
| D489 | Leronlimab | Biological drug | DB05941 | -- | -- | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0820 | DB05501 | investigational | small molecule | AMD-070 | Target associated | Details |
| R0898 | DB05906 | investigational | biotech | CCR5 mAb | Target associated | Details |
| R1031 | DB06497 | investigational | small molecule | Aplaviroc | Target associated | Details |
| R1071 | DB06652 | investigational | small molecule | Vicriviroc | Target associated | Details |
| R1460 | DB12698 | approved; investigational | biotech | Ibalizumab | Target associated | Details |
| R1469 | DB12960 | investigational | small molecule | INCB-9471 | Target associated | Details |
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species | |
|---|---|---|---|---|---|---|---|
| B000001 | CHEMBL10 | Small molecule | SB-203580 | 377.44 | C21H16FN3OS | NEUTRAL | Details |
| B000004 | CHEMBL100336 | Small molecule | -- | 532.77 | C34H48N2O3 | ZWITTERION | Details |
| B000013 | CHEMBL100596 | Small molecule | -- | 518.74 | C33H46N2O3 | ZWITTERION | Details |
| B000014 | CHEMBL1006 | Small molecule | AMIFOSTINE | 214.23 | C5H15N2O3PS | ZWITTERION | Details |
| B000021 | CHEMBL1009 | Small molecule | LEVODOPA | 197.19 | C9H11NO4 | ZWITTERION | Details |
| B000024 | CHEMBL100958 | Small molecule | -- | 532.77 | C34H48N2O3 | BASE | Details |
| B000025 | CHEMBL101 | Small molecule | PHENYLBUTAZONE | 308.38 | C19H20N2O2 | ACID | Details |
| B000031 | CHEMBL101165 | Small molecule | -- | 184.24 | C12H12N2 | NEUTRAL | Details |
| B000032 | CHEMBL101168 | Small molecule | -- | 134.14 | C6H6N4 | NEUTRAL | Details |
| B000039 | CHEMBL101333 | Small molecule | -- | 608.87 | C40H52N2O3 | BASE | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A47009 | 30179264 | Hepatology | Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice. | Details |
| A47734 | 32739404 | Antiviral Res | The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. | Details |
| A51305 | 35749425 | PLoS Pathog | Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. | Details |